Journal article
Effectiveness and safety of rivaroxaban vs. warfarin in non-valvular atrial fibrillation patients with a non-sex-related CHA2DS2-VASc score of 1
Abstract
AIMS: To compare the effectiveness and safety of standard-dose rivaroxaban (20 mg o.d.) and warfarin in non-valvular atrial fibrillation (NVAF) patients with a non-sex-related CHA2DS2-VASc score of 1.
METHODS AND RESULTS: Analysis of United States Truven MarketScan claims from November 2011 to December 2016 for anticoagulant-naïve NVAF patients with a single non-sex-related stroke risk factor assigned 1-point in the CHA2DS2-VASc score and …
Authors
Coleman CI; Turpie AGG; Bunz TJ; Eriksson D; Sood NA; Baker WL
Journal
European Heart Journal - Cardiovascular Pharmacotherapy, Vol. 5, No. 2, pp. 64–69
Publisher
Oxford University Press (OUP)
Publication Date
April 1, 2019
DOI
10.1093/ehjcvp/pvy025
ISSN
2055-6837
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
Administrative Claims, HealthcareAnticoagulantsAtrial FibrillationDatabases, FactualDecision Support TechniquesEmbolismFactor Xa InhibitorsFemaleHemorrhageHumansMaleMiddle AgedPredictive Value of TestsRetrospective StudiesRisk AssessmentRisk FactorsRivaroxabanStrokeTime FactorsTreatment OutcomeUnited StatesWarfarin